Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I bioequivalence trial of extended- versus immediate-release formulation of topiramate, and the effects of food on extended-release topiramate pharmacokinetics in volunteers

Trial Profile

Phase I bioequivalence trial of extended- versus immediate-release formulation of topiramate, and the effects of food on extended-release topiramate pharmacokinetics in volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Topiramate (Primary)
  • Indications Epilepsy; Migraine
  • Focus Pharmacokinetics

Most Recent Events

  • 21 Apr 2016 Results of pooled analysis from three phase I and two phase III studies assessing the differentiating features of Topiramate (extented release capsules and immediate release) presented at the 68th Annual Meeting of the American Academy of Neurology
  • 06 Dec 2011 Results were presented at the 65th Annual Meeting of the American Epilepsy Society (AES-2011)
  • 26 Sep 2011 Results were presented at the Annual Meeting of the American Neurological Associations (ANA-2011).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top